Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients

Response to Targher et al.

  1. Roger K. Schindhelm, MD, PHD, MEPI12,
  2. Robert J. Heine, MD, PHD, FRCP1 and
  3. Michaela Diamant, MD, PHD1
  1. 1Department of Endocrinology/Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands
  2. 2Department of Clinical Chemistry, Isala Clinics, Zwolle, the Netherlands
  1. Address correspondence to Roger K. Schindhelm, MD, PHD, Department of Clinical Chemistry, Isala Clinics, Loc. Sophia, P.O. Box 10400, 8000 GK Zwolle, Netherlands. E-mail: r.k.schindhelm{at}isala.nl

We read with great interest the recent article by Targher et al. (1) reporting the prevalence of nonalcoholic fatty liver disease (NAFLD) and associated cardiovascular disease (CVD) risk factors in patients with type 2 diabetes.

Proper identification of patients with NAFLD is of major importance for adequate treatment and reduction of CVD risk in type 2 diabetic patients. However, routine ultrasound examination of the abdomen for the screening of hepatic steatosis in combination with serologic …

| Table of Contents